However, the prognosis for PTCL is poor with conventional cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or CHOP-like regimens, with a 5-year overall survival (OS) of 10–30%, with the exception of anaplastic lymphoma kinase (ALK)-positive ALCL, mycosis fungoides, and subcutaneous panniculitis-like T cell lymphoma1,2. Here, ALK is linked to anaplastic large cell lymphoma.